Table 3. Plasma ctDNA analysis of GIST patients with localized/locally advanced disease.
| Patient | Primary GIST location | Disease status | Mutation | Mutant allelic frequency | |
|---|---|---|---|---|---|
| 7 | Rectum | Localized | KIT exon 11 | c.1676T>A | 1,95% |
| 9 | Stomach | Localized | KIT exon 11 | c.1671_1672delinsTG | 0,00% |
| 10 | Stomach | Localized | KIT exon 11 | c.1669_1674del | 0,00% |
| 12 | Stomach | post-surgery | KIT exon 11 | c.1673_1717del | 0,00% |
| 13 | Stomach | Localized | KIT exon 11 | c.1662_1674delinsGGAAGAA; | 0,00% |
| 17 | Stomach | Localized | KIT exon 11 | c.1669_1674del | 0,00% |
| 19 | Small bowel | Localized | KIT exon 11 | c.1669T>C | 0,00% |
| 37 | Stomach | Localized | KIT exon 11 | c.1679 T>A | 0,00% |
Primary tumors of 7 of these patients were tested positive with the assay (patient 7–19 see Table 1, patient 37 data not shown, tumor of patient 38 was not positive). Samples were taken before start of any treatment.